Similar articles

• Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury.

  Cardinal H, Dieudé M, Brassard N, Qi S, Patey N, Soulez M, Beillevaire D, Echeverry F, Daniel C, Durocher Y, Madore F, Hébert MJ. Cardinal H, et al. Am J Transplant. 2013 Apr;13(4):861-874. doi: 10.1111/ajt.12168. Epub 2013 Feb 22. Am J Transplant. 2013. PMID: 23432943
• Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat.

  Joosten SA, van Dixhoorn MG, Borrias MC, Benediktsson H, van Veelen PA, van Kooten C, Paul LC. Joosten SA, et al. Am J Pathol. 2002 Apr;160(4):1301-10. doi: 10.1016/S0002-9440(10)62557-6. Am J Pathol. 2002. PMID: 11943715 Free PMC article.
• Serum antibodies to heparan sulfate glycosaminoglycans in Guillain-Barré syndrome and other demyelinating polyneuropathies.

  Pestronk A, Choksi R, Yee WC, Kornberg AJ, Lopate G, Trotter J. Pestronk A, et al. J Neuroimmunol. 1998 Nov 2;91(1-2):204-9. doi: 10.1016/s0165-5728(98)00182-9. J Neuroimmunol. 1998. PMID: 9846837
• Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity.

  Dragun D, Catar R, Philippe A. Dragun D, et al. Kidney Int. 2016 Aug;90(2):280-288. doi: 10.1016/j.kint.2016.03.019. Epub 2016 May 14. Kidney Int. 2016. PMID: 27188505 Review.
• Injury derived autoimmunity: Anti-perlecan/LG3 antibodies in transplantation.

  Dieudé M, Cardinal H, Hébert MJ. Dieudé M, et al. Hum Immunol. 2019 Aug;80(8):608-613. doi: 10.1016/j.humimm.2019.04.009. Epub 2019 Apr 24. Hum Immunol. 2019. PMID: 31029511 Review.